登录 注册 会员服务 联系我们

Ten-Year Survival and Cost Following Breast Cancer Recurrence: Estimates from SEER-Medicare Data

  • Published:2008-03 Issue:2 Volume:11 Page:213-220
  • ISSN:1098-3015
  • Container-title:Value in Health
  • language:en
  • Short-container-title:Value in Health

Author:

Stokes Michael E.,Thompson David,Montoya Eduardo L.,Weinstein Milton C.,Winer Eric P.,Earle Craig C.

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference20 articles.

1. Annual hazard rates of recurrence for breast cancer after primary therapy;Saphner;J Clin Oncol,1996

2. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? [Abstract];Hortobagyi;Proc Am Soc Clin Oncol,2004

3. The role of aromatase inhibitors in early breast cancer;Chung;Curr Treat Options Oncol,2003

4. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer;Coombes;N Engl J Med,2004

Cited by 82 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3